Revumenib (SNDX-5613)

Menin Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
AUGMENT-101-2A
(monotherapy)
R/R KMT2Ar ALL
AUGMENT-101-2B
(monotherapy)
R/R KMT2Ar AML
AUGMENT-101-2C
(monotherapy)
R/R mNPM1 AML
AUGMENT-102
(chemotherapy combination)
R/R KMT2Ar and
mNPM1 acute leukemia
BEAT-AML
(ven/aza combination)
Frontline KMT2Ar and
mNPM1 AML
INTERCEPT
(monotherapy)
MRD- progression in KMT2Ar and
mNPM1 AML
Colorectal Cancer
(monotherapy)
Unresectable metastatic microsatellite stable CRC

Axatilimab (SNDX-6352)

CSF-1R mAB
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
AGAVE-201
(monotherapy)
Chronic GVHD

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
Entinostat
Under internal review

Revumenib (SNDX-5613)

Menin Inhibitor

AUGMENT-101-2A

R/R KMT2Ar ALL

Pivotal

AUGMENT-101-2B

R/R KMT2Ar AML

Pivotal

AUGMENT-101-2C

R/R mNPM1 AML

Pivotal

AUGMENT-102

R/R KMT2Ar and mNPM1 acute leukemia

Phase 1

BEAT-AML

Frontline KMT2Ar and mNPM1 AML

Phase 1

INTERCEPT

MRD- progression in KMT2Ar and
mNPM1 AML

Phase 1

Colorectal Cancer

Unresectable metastatic microsatellite stable CRC

Phase 1

Axatilimab (SNDX-6352)

CSF-1R mAB

AGAVE-201

Chronic GVHD

Pivotal

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor

Entinostat

Under Internal Review